FDA Compliance for Peptide Clinics

The regulatory framework governing peptide therapies in the United States involves multiple federal agencies, legal authorities, and regulatory pathways that interact in complex ways. For a peptide clinic practitioner, understanding this framework is not optional, misunderstanding the regulatory landscape can result in prescribing practices that expose patients to unsafe products, create legal liability for the prescriber, and undermine the credibility of the entire peptide medicine field.

The Food, Drug, and Cosmetic Act (FD&C Act) gives the FDA authority over drugs and devices, including the authority to determine what constitutes a "new drug" requiring FDA approval before marketing. Under the FD&C Act, any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals is a drug, this is an extremely broad definition that encompasses virtually every peptide used therapeutically. For a drug to be legally marketed in the US, it must either be FDA-approved through the NDA/ANDA/BLA pathways, or it must meet one of the specific exemptions provided in the FD&C Act, most importantly for peptide clinics, the compounding exemptions provided in Sections 503A and 503B (PMID 30005109).

The Drug Enforcement Administration (DEA) regulates controlled substances under the Controlled Substances Act (CSA). Most therapeutic peptides, including insulin, semaglutide, and commonly used GH secretagogues, are not federally scheduled controlled substances, but scheduling status should be verified before prescribing. Notable exceptions: bremelanotide (Vyleesi) is not scheduled. Human growth hormone is not a federally scheduled controlled substance in the United States, but federal law restricts its distribution to approved uses and some states regulate it more strictly, so prescribers should check current federal and state requirements). The anabolic peptides most at risk for DEA scheduling are IGF-1 and certain androgens-related compounds, practitioners should verify current scheduling status for any peptide before prescribing, as the DEA can add substances to the schedule through a regulatory process that does not require Congressional action.

State medical boards regulate physician prescribing practices and can discipline or revoke the licenses of physicians whose prescribing practices fall outside accepted standards of care or violate state law, even if no federal law is violated. Some states have enacted specific regulations restricting or prohibiting certain peptide prescribing practices (particularly for weight loss, athletic enhancement, or anti-aging applications). Practitioners must be familiar with their state medical board's position on peptide therapy and off-label prescribing generally, and should consult with a healthcare attorney familiar with their specific state's regulatory environment before establishing a peptide therapy practice.